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Abstract
Hearing impairment is a significant disability.  According to the World Health Organization (WHO), more than 80% of  the 
world’s approximately 120 million people with hearing impairment live in developing countries.  Cochlear implant is the only 
therapeutic intervention for those with severe-profound sensorineural hearing loss. We are  reporting an  interesting case of  
the very first cochlear implant operation carried out in Uganda. The patient was a 23 year old male whose presenting com-
plaint was inability to hear in the left ear for three and a half  years and in the right ear for one year. He had been  treated for 
TB(Tuberculosis) mastoiditis . After the 8 months of  treatment, the otorrhea persisted and he underwent a tympanomas-
toidectomy on the same ear.  He reported no familial history of  hearing loss. On examination,  ENT examination revealed a 
small pars flaccida retration pocket of  the right tympanic membrane with cholesteatoma. The left ear had  an intact tympanic 
membrane. Pure tone audiometry revealed profound sensorineural hearing loss in both ears( see attached PTA results), CT 
scan of  the temporal bone showed normal inner ear anatomy bilaterally and mild sclerotic changes in both mastoid bones. 
He then had surgery on his right ear which included  cochlear implantation.  The cochlear implant (CI) was activated on the 
first postoperative day remotely via internet with the help of  the cochlear implant team at New York University Cochlear 
Implant Center and the patient was immediately able to appreciate some sounds. He  received a pneumococcal vaccine on 
the first postoperative day and was discharged  the following day.
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Introduction
Hearing impairment is a significant disability.  Accord-
ing to the World Health Organization (WHO), more 
than 80% of  the world’s approximately 120 million 
people with hearing impairment live in developing 
countries.  The causes for hearing loss are varied in-
cluding presbycusis which causes high frequency loss 
with advanced age, chronic infectious diseases such as 
otitis media, meningitis, tuberculosis, congenital factors, 
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Cochlear implant is the only therapeutic intervention 
for those with severe-profound sensorineural hearing 
loss.  This intervention aids the patient’s speech and 
communication skills and therefore improves on his or 
her general state of  well-being, ability to work and con-
tribute to society.   Unfortunately, at present, cochlear 
implants are unavailable for deaf  people in developing 
countries such as Uganda due to financial and infra-
structural constraints.1 
Such devices are expensive and surgical implantation is 
only the first part of  a process towards restoring hear-
ing which involves speech therapy and frequent visits to 
the audiologist for device programming. 
Feasibility for whether a cochlear implant will actually 
work in a patient is done in a stepwise manner to an-
swer two questions. These questions are; 
Are there:
a) Any cochleovestibular anomalies such as evidence of  
luminal obstruction following infection or secondary to 
trauma leading to neo-ossification. 
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b) Any findings that might complicate surgery such as 
anatomic variants. 
These questions are answered by preoperative imaging 
either by CT scan or MRI and a complete audiometric 
evaluation. Other contraindications may include ab-
sence of  a cochlear nerve which the implant is designed 
to stimulate and medical cormorbidities which preclude 
undergoing surgery which can require between 1-3 
hours. Factors that predict the greatest success include 
post-lingual deafness so that patients have already ac-
quired speech and language skills and a short duration 
of  deafness since the longer the ear has been without 
auditory stimulation, the lower the expectations for 
speech performance after cochlear implantation. 
 
For successful cochlear implantation the goal is to by-
pass the inner ear by converting acoustic mechanical 
energy into electrical impulses transmitted to the exist-
ing surviving ganglion cell population in the cochlear 
which are then relayed via the cochlear nerve to the au-
ditory brainstem and ultimately to the cerebral cortex2. 
In summary, success of  the cochlear implant not only 
depends on the device itself, but also on patient selec-
tion, surgical skills, and post-surgical rehabilitation1.
History
The patient was a 23 year old male whose presenting 
complaint was inability to hear in the left ear for three 
and a half  years and in the right ear for one year. The 
patient reported that he developed pus discharge from 
the left ear about 4 years prior to being considered a 
candidate for a cochlear implant. This ear infection did 
not respond to standard treatment and was later diag-
nosed on bacterial and ZN (Ziehl-Neelsen) stains as 
Tuberculosis of  the ear. He was treated with antituber-
culous medications for 8 months. After the 8 months 
of  treatment, the otorrhea persisted and he underwent 
a tympanomastoidectomy on the same ear. During  re-
covery, the patient reports that he could not hear from 
this ear completely. 
About 1 year prior to the cochlear implant operation, 
he developed pain and ear discharge in the right ear for 
which he was treated with some unspecified ear drops. 
The pain subsided but later he said he developed re-
duced hearing that slowly progressed to profound hear-
ing loss in that ear. There was no history of  trauma to 
his head or ears.
He reported no familial history of  hearing loss. At the 
time he became deaf, he was in high school.
On examination, the patient was in good general con-
dition. ENT examination revealed a small pars flaccida 
retration pocket of  the right tympanic membrane with 
cholesteatoma. The left ear had an  intact tympanic 
membrane . Pure tone audiometry revealed profound 
sensorineural hearing loss in both ears( see attached 
PTA results), CT scan of  the temporal bone showed 
normal inner ear anatomy (both cochlear and vestibular 
apparatus) bilaterally and mild sclerotic changes in both 
mastoid bones. 
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An MRI of  the  patient’s temporal bone was not done, 
partly because the patient’s cochlear apparatus was 
found to be normal on CT scan and also because of  the 
high cost of  carrying out an MRI scan.
He then had surgery on his right ear. Of  the two ears, 
the right ear inspite of  having cholesteatoma was con-
sidered to be safer than the left ear which had previous-
ly been diagnosed with tuberculosis . 
The following procedures were done  subtotal petrou-
sectomy, blind sac of  the external auditory canal, ob-
struction of  the eustacian tube  and fat graft to the cav-
ity. Then we did the well for the CI receiver stimulator 
behind the mastoid, made a trough to the mastoid and 
opened the cochlear  just inferior and anterior to the 
round window.  The electrode was then inserted  with 
an advance off  stylet technique for a full insertion.  The 
device was activated intra-operatively and impedances 
were obtained and neural response telemetry obtained. 
This confirmed the device integrity and the nerve re-
sponses to stimulation.  We obtained a plain Stenver’s 
view  xray confirming electrode position with in the 
cochlear without kinks or bends.
The wounds were closed in the normal fashion and a 
firm mastoid dressing was placed. On the first postop-
erative day, we obtained threshold and comfort levels 
on each electrode and activated the  processor. Then 
we obtained open set speech understanding to words 
and sentences.      
The cochlear implant (CI) was activated on the first 
postoperative day remotely via internet with the help 
of  the cochlear implant team at New York University 
Cochlear Implant Center and the patient was immedi-
ately able to appreciate some sounds.This was done us-
ing an application that had been put on one of   Prof.
Roland’s laptop computer. The application is called 
Custom Sound by Cochlear (the company that manu-
factures the cochlear implant that was used). The pa-
tient  also received a pneumococcal vaccine on the first 
postoperative day and was discharged from hospital the 
following day.
Follow up appointments were arranged for him with 
the local ENT team in Uganda, a speech therapist, and 
the Cochlear Implant center in New York University. 
After a usual postoperative course, he joined his mother 
in working in their family business. 
Discussion 
Hearing loss is not an uncommon problem in Ugan-
da. Westerberg et al3 carried out a study in Uganda and 
found that the prevalence of  disabling hearing impair-
ment was 11.7% in adults and 10.2% in children. There 
are many causes of  profound sensorineural hearing loss, 
however the cause of  hearing loss in this young man is 
unknown. The incidence of  tuberculosis otitis media 
has been reported to be 0.04% to 0.9% of  all Chron-
ic Suppurative Otitis Media (CSOM) in the developed 
countries4,5 Although he suffered from TB( tuberculo-
sis) of  the ear  and was treated with antiTB drugs for 
8months, there is still no clear evidence to incriminate 
the disease process or its treatment as the cause of  the 
profound sensorineural hearing loss in both ears.
Normally, active chronic suppurative otitis media is re-
garded as a contraindication for cochlear implantation. 
In case of  a radical cavity after surgical treatment for 
cholesteatoma, the electrode covered by the epithelial 
lining of  the mastoid will likely become exposed or ex-
truded. Under these circumstances some studies6, 7,have 
shown that the some of  the following procedures can 
be done to protect the electrode. These include subtotal 
petrosectomy, obliteration of  the middle ear cleft with 
abdominal fat, mastoid obliteration and the blindsac 
closure of  the external ear canal before cochlear im-
plantation.
In this particular case, the operation was carried out in 
an infected ear. At the time of  the operation, the right 
ear had a tympanic membrane perforation and scanty 
aural discharge and patient had been using ear drops to 
control the infection. And to safe guard against future 
complications in the same ear, the eustachian tube was 
completely blocked and the ear canal ‘blind-sacked’. 
This we hope will protect the implant device from mid-
dle and outer ear infections. 
Wei et al8 carried out a study that showed that vacci-
nating cochlear implant patients against S pneumonia 
was protective against pneumococcal meningitis. Oth-
er studies have also showed that children with cochlear 
implants are at a higher risk for meningitis than chil-
dren with hearing loss who have not received  cochlear 
implants9-11.  In 2003, the CDC and FDA announced 
that children with cochlear implants are at a slightly in-
creased risk of  bacterial meningitis12. Though this risk is 
small, it is still 30 times higher than children in the gen-
eral population, without proper immunizations. A study 
of  4,265 American children who received implants be-
tween 1997 and 2002 concluded that recipient children 
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had a risk of  pneumococcal meningitis more than 30 
times greater than that for children in the general pop-
ulation. A later, UK-based, study found that while the 
incidence of  meningitis in implanted adults was signifi-
cantly higher than the general population, the incidence 
in children was not different than in the general popu-
lation13. Therefore to further protect our patient from 
any anticipated future complications like pneumococcal 
meningitis, he was given the pneumococcal vaccine on 
the first postoperative day.   
 
Other than the ear infection, this young man was a good 
cochlear implant candidate because he had just recent-
ly lost his hearing (short duration of  deafness) and his 
speech was well developed (post-lingual) by then. This 
means that rehabilitating him after the cochlear implant 
had been activated would require less intensive therapy. 
Still, the device is not an immediate fix and the patient 
still needed regular rehabilitation sessions to maximize 
performance. The candidate was also very motivated as 
far as wanting to receive the cochlear implant and being 
able to hear again was concerned and he had strong 
support from his parents and from the three speech 
therapists in Uganda. These factors are also very im-
portant in his success.
As of  December 2010, approximately 219,000 people 
worldwide have received cochlear implants; in the U.S., 
roughly 42,600 adults and 28,400children are recipients. 
The vast majority are in developed countries due to the 
high cost of  the device, surgery and post-implantation 
therapy14,15, This cochlear implant operation was the 
first one done in Uganda and possibly the first in the 
East African region(no published report of  any done 
before in this region). This compared to the numbers 
of  cochlear implant operations done in the developed 
countries is too small a number but this is a very good 
starting point for us in Uganda. We have since then car-
ried out another cochlear implant surgery on an adult 
male which was also successful.
Over the last 10 years, implant centers have begun to 
use the internet to allow audiologists to monitor devic-
es from remote locations. In a study by Shapiro and 
colleagues16, 8 patients were evaluated; 4 were moni-
tored in situ and 4 from a remote location (cochlear 
implant center)in an effort to determine the feasibility 
and efficacy of  remote monitoring compared with in 
situ monitoring. The results showed the average audiol-
ogist’s time for remote testing was 9 minutes compared 
with 93 minutes required for performing in situ testing. 
In fact according to the cochlear implant team from 
New York University, this was the very first time they 
programmed/ activated a cochlear implant device on 
a patient from such a long distance using telemedicine 
(New York to Uganda, Africa).   
The young man is doing well and is able to hear well six 
years after his operation. His hearing was assessed using 
an audiometer and his hearing was found to be very 
good ( see attached hearing test results).
 
As expected his hearing is much better in a quiet en-
vironment compared to more difficult listening con-
ditions. This agreed with earlier studies which showed 
that for a patient with severe to profound sensorineural 
hearing impairment in both ears, their hearing can be 
restored to a good extent by implanting them with a 
cochlear implant17.
This cochlear implant operation is a very important 
landmark for Uganda in the field of  otology, and we 
are grateful to our colleagues from New York Univer-
sity, USA and our Canadian friends from the Uganda 
Hearing Project for their collaborative effort and all the 
support they have given to us. This however is like the 
proverbial drop in the ocean concerning the need for 
otologic care for the many Ugandan patients with ear 
disease, but represents an important first step toward 
meeting this important need. 
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